Linked e-resources
Details
Table of Contents
Chapter 1 Epidemiology of Renal Cell Carcinoma
Chapter 2 Hereditary Renal Cell Carcinoma
Chapter 3 Molecular Genetics of Renal Cell Carcinoma
Chapter 4 Pathology of Renal Cell Carcinoma
Chapter 5 Imaging Features of Renal Cell Carcinoma: Differential Diagnosis, Staging and Post-Treatment Evaluation
Chapter 6 Treatment Overview
Chapter 7 Natural History and Active Surveillance
Chapter 8 Surgical Treatment for Renal Cell Carcinoma
Chapter 9 Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma
Chapter 10 Tyrosine-Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, Pazopanib
Chapter 11 Mammalian Targets of Rapamycin Inhibitors: Temsirolimus, Everolimus
Chapter 12 Immunotherapy for Renal Cell Carcinoma (RCC): Including Immune Checkpoint Blockade Therapy
Chapter 13 Treatment for Non-Clear Cell Renal Cell Carcinoma
Chapter 14 Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy
Chapter 15 Refractory Mechanisms
Chapter 16 Optimization of Therapy by Pharmacokinetic: Pharmacodynamic Analyses.
Chapter 2 Hereditary Renal Cell Carcinoma
Chapter 3 Molecular Genetics of Renal Cell Carcinoma
Chapter 4 Pathology of Renal Cell Carcinoma
Chapter 5 Imaging Features of Renal Cell Carcinoma: Differential Diagnosis, Staging and Post-Treatment Evaluation
Chapter 6 Treatment Overview
Chapter 7 Natural History and Active Surveillance
Chapter 8 Surgical Treatment for Renal Cell Carcinoma
Chapter 9 Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma
Chapter 10 Tyrosine-Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, Pazopanib
Chapter 11 Mammalian Targets of Rapamycin Inhibitors: Temsirolimus, Everolimus
Chapter 12 Immunotherapy for Renal Cell Carcinoma (RCC): Including Immune Checkpoint Blockade Therapy
Chapter 13 Treatment for Non-Clear Cell Renal Cell Carcinoma
Chapter 14 Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy
Chapter 15 Refractory Mechanisms
Chapter 16 Optimization of Therapy by Pharmacokinetic: Pharmacodynamic Analyses.